Genetic engineering raises legitimate ethical concerns on every side of the debate, and there is no single yes-or-no answer. The ethics depend heavily on what is being edited, why, and who benefits. Most people support using gene editing to treat serious diseases, while far fewer are comfortable with editing for cosmetic traits or physical enhancement. The real ethical landscape is more nuanced than either camp suggests, touching safety risks, disability rights, environmental consequences, economic access, and the rights of future generations who cannot consent.
The Line Between Treatment and Enhancement
Public opinion research consistently shows broad support for therapeutic uses of gene editing and strong resistance to non-disease applications like altering physical characteristics. That distinction, treating illness versus improving traits, is the ethical fault line most people intuitively recognize. Editing a gene to prevent sickle cell disease feels different from editing one to change eye color, even though the underlying technology is identical.
The problem is that the boundary between treatment and enhancement is blurry. Is editing out a gene linked to a higher cancer risk a treatment or an upgrade? What about genes associated with conditions that some people don’t consider diseases at all, like deafness or dwarfism? These gray areas make it difficult to draw a regulatory line that everyone agrees on, and they feed into deeper concerns about who gets to define “normal.”
Somatic Editing vs. Germline Editing
One of the most important ethical distinctions in genetic engineering is which cells get edited. Somatic cell editing changes the DNA in specific tissues of a living person. Those changes stay with that individual and are not passed on to children. Germline editing, by contrast, alters reproductive cells or embryos, meaning the modifications become heritable. Every future generation would carry them.
Somatic editing is far less controversial. It works like a highly targeted medical treatment: one patient, one outcome. The first CRISPR-based therapy, Casgevy, was approved by the FDA in late 2023 for sickle cell disease in patients 12 and older. It takes a patient’s own blood stem cells, edits them to boost production of a type of hemoglobin that improves oxygen delivery, and transplants them back in a single dose. This is somatic editing in practice, and it represents the kind of application most ethicists consider defensible.
Germline editing is where the ethical alarm bells ring loudest. The gene therapy field has determined that approaches leading to unintentional modification of the germline should not be permitted. The core issue is consent: future children and their descendants cannot agree to permanent changes in their DNA. And even somatic therapies carry some germline risk. When editing is performed in the body (rather than on cells removed and returned), there is potential for the editing tools to reach reproductive cells, particularly if treatment occurs during fetal development before germline and somatic cells have fully separated.
Safety Is Still a Moving Target
The technology itself poses risks that make the ethics harder to resolve. CRISPR-Cas9, the most widely used gene-editing tool, can cut DNA at unintended locations in the genome. A single guide RNA designed to target one gene can recognize DNA sequences with as many as three to five mismatched base pairs, meaning there could be thousands of possible binding sites for any given edit in a human genome.
In laboratory studies, unmodified Cas9 has shown off-target editing rates as high as 50 to 60 percent at sites with a single mismatch, and still 7 to 12 percent even with three mismatches. At some tested sites, off-target mutation rates ranged from 9 to 94 percent. These unintended cuts can cause deletions, inversions, and large-scale chromosomal rearrangements. Newer engineered versions of Cas9 have reduced off-target rates significantly, bringing most sites below 4 percent, but “significantly reduced” is not the same as eliminated. For somatic therapies in a single patient, that residual risk may be acceptable depending on the severity of the disease. For germline changes that propagate indefinitely, the stakes of even a rare error are vastly higher.
The He Jiankui Case
The most prominent example of genetic engineering crossing an ethical line happened in 2018, when Chinese biophysicist He Jiankui announced he had edited the genomes of twin embryos to make them resistant to HIV. The experiment, which ran from March 2017 to November 2018, violated nearly every ethical standard in the field. An investigation by Guangdong Province found that He had intentionally evaded oversight, recruited eight couples using a fake ethics review certificate, and had others substitute for volunteers during blood tests because HIV carriers are not permitted to use assisted reproduction in China.
He’s own published ethics criteria stated that gene editing is “only permissible when the risks of the procedure are outweighed by a serious medical need.” HIV resistance in embryos that were not infected did not meet that bar. The experiment also disregarded multiple requirements from the U.S. National Academies’ framework on human genome editing, including those related to transparency and public input. He was sentenced to prison. The case is now a reference point for why governance matters: without enforceable rules, individual actors can make irreversible decisions on behalf of people who do not yet exist.
What the Disability Community Objects To
A frequently overlooked ethical dimension comes from people living with the very conditions gene editing aims to prevent. Many in the disability community see genetic engineering as a threat to their identity and social standing. The majority of people with genetic disabilities report that it would be a loss to society to have fewer people with their particular condition. The concern is not abstract. If society increasingly treats certain conditions as problems to be engineered away, public awareness and community support for those conditions may shrink. People currently living with those traits can experience real emotional harm from the message that their existence is something the wider society prefers to avoid.
This perspective draws on the social model of disability, which holds that many of the hardships disabled people face come from social barriers, not from their bodies. Editing out deafness, for example, assumes deafness is a deficit rather than a difference. That assumption has consequences for funding, for community infrastructure, and for how disabled people are treated in daily life.
Environmental Risks of Gene Drives
Genetic engineering ethics extend well beyond humans. Gene drives, engineered genetic systems designed to spread a trait through a wild population faster than normal inheritance would allow, are being developed to fight diseases like dengue and malaria by modifying mosquito populations. But their ecological implications are enormous and largely untested.
A gene drive is fundamentally different from a contained lab experiment. It is designed to spread, and possibly persist, in the environment indefinitely. The National Academies has noted that the ecological risk assessment for gene-drive organisms is more comparable to evaluating an invasive species than a standard genetically engineered crop. Key unanswered questions include whether the modified trait will remain stable across generations, whether the genetic construct can jump to non-target species, and what happens to the broader ecosystem when a common species is suppressed or eliminated.
Removing one mosquito species, for instance, could open niche space for a competing species or alter predator-prey dynamics up and down the food chain. Proposed “reversal drives” meant to undo an unintended outcome could themselves introduce new ecological effects. The science of gene drives is advancing far faster than the ecological research needed to assess their safety.
Who Can Afford Gene Therapy
Even when genetic engineering is used ethically in a clinical sense, its benefits may not be distributed ethically. Zolgensma, a gene therapy for spinal muscular atrophy, costs approximately 1.9 million euros per treatment. Casgevy, the CRISPR sickle cell therapy, also carries a price tag in the millions when you factor in the stem cell transplant process. These are one-time treatments for devastating diseases, and financial analysis suggests the pricing may be justified from an investment standpoint. But justification for the manufacturer does not translate into access for patients.
Sickle cell disease disproportionately affects people of African descent, many of whom live in countries or communities with limited healthcare resources. If the most transformative gene therapies are available only to those who can pay seven figures, genetic engineering risks becoming a technology that widens health disparities rather than closing them. The same pattern has already played out in agriculture: larger, better-connected farmers adopted genetically modified crops earlier and captured greater economic returns, while smallholders faced higher seed costs and vulnerability to market shifts. For millions of small-scale farmers, seeds are part of cultural heritage and community identity. Patented, corporate-controlled seed varieties are seen as a direct threat to seed sovereignty and traditional knowledge.
Governance Is Uneven and Incomplete
In 2018, the World Health Organization established a global expert committee to develop governance standards for human genome editing across somatic, germline, and heritable applications. The resulting framework identifies values and principles for oversight, reviews institutional tools and processes, and puts forward scenarios for how governance should work in practice. But frameworks are advisory. Enforcement depends on national laws, and those vary dramatically.
Some countries ban germline editing outright. Others have no specific regulations at all. Public research institutions frequently struggle to commercialize their technologies because private companies hold key patents on genes or transformation methods, concentrating power in a small number of corporations. CRISPR-based tools offer the potential to democratize genetic engineering by allowing public institutions to develop locally adapted solutions without the intellectual property barriers of earlier technologies, but that potential is far from realized.
The ethical question is not just whether genetic engineering can be done safely or for good reasons. It is whether the world has the governance infrastructure to ensure it is done equitably, transparently, and with meaningful input from the people most affected, including those who cannot yet speak for themselves.